DSGN

Design Therapeutics is a pre-revenue, clinical-stage biotech whose entire equity story rides on its GeneTAC platform and, in the near term, a single asset — DT-216P2 in Friedreich ataxia. FY2025 revenue was $0, net income was -$69.8M (worsening from -$49.6M), and operating cash burn ran at -$54.4M while R&D expense jumped +33.3% YoY to $59.1M. Diluted shares outstanding grew 8.6% to 61.7M, signaling that equity issuance is already part of the funding mix. At $14.30 the implied market cap is ~$882M against $213M of book equity and a -$297M accumulated deficit — i.e. the price is paying entirely for an unproven pipeline.

Liquidity looks better than the $16.9M cash line suggests: current assets of $224M against current liabilities of $13.1M imply roughly ~$207M of additional short-term investments, giving ~3–4 years of runway at the current burn — but R&D is accelerating, and management itself flags 'our ability to obtain funding for our operations, including funding necessary to initiate and complete clinical trials' as a risk. The balance sheet (liabilities/equity 0.06x) is unlevered, but ROE of -32.8% reflects the reality that equity is being consumed, not compounded.